Clinical trial to evaluate zimberelimab and domvanalimab in combination with chemotherapy versus pembrolizumab with chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer.

THE MAIN GOAL OF THIS STUDY IS TO DETERMINE WHETHER ZIM ALONE OR IN COMBINATION WITH DOM AND CHEMOTHERAPY IS SAFE AND EFFECTIVE WHEN GIVEN TO PATIENTS WITH THE TYPE OF CANCER YOU HAVE. THE FIRST STANDARD TREATMENT APPROVED FOR METASTATIC NSCLC WITHOUT GENE ALTERATIONS IS ANTI-PD-(L)1 IMMUNOTHERAPY, WHICH IS A DRUG THAT HELPS THE IMMUNE SYSTEM TARGET CANCER CELLS FOR DESTRUCTION, COMBINED WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY. THE STUDY WILL ALSO ATTEMPT TO UNDERSTAND HOW THE COMBINATION OF ZIM, DOM, AND CHEMOTHERAPY COMPARES TO THE CURRENTLY APPROVED STANDARD TREATMENT (PEMBROLIZUMAB WITH CHEMOTHERAPY) IN PEOPLE WITH THE TYPE OF CANCER YOU HAVE. THIS STUDY WILL ALSO SEEK TO LEARN ABOUT YOUR QUALITY OF LIFE AND HEALTH STATUS DURING THE STUDY.